Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies

Antoniou, A., Pharoah, P.D.P., Narod, S., Risch, H.A., Eyfjord, J.E., Hopper, J.L., Loman, N., Olsson, H. +25 more·2003·The American Journal of Human Genetics
DOI 10.1086/375033

Cited by (1,009)

Items 301–400 of 1,009

  1. BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50
    Robert W. Haile, Duncan C. Thomas, Valerie M. McGuire, Anna Felberg, Esther M. John, Roger Laughlin Milne, John Llewelyn Hopper, Mark A. Jenkins, A. Joan Levine, Mary M. Daly et al. · 2006 · Cancer Epidemiology Biomarkers & Prevention
  2. Estimated Risk of Radiation-Induced Breast Cancer From Mammographic Screening for Young BRCA Mutation Carriers
    Amy Berrington de González, Christine D. Berg, Kala Visvanathan, Mark E. Robson · 2009 · JNCI Journal of the National Cancer Institute
  3. Perturbation of Rb, P53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer
    Szabova, Ludmila, Yin, Chaoying, Bupp, Sujata, Guerin, Theresa M., Schlomer, Jerome J., Householder, Deborah B., Baran, Maureen L., Yi, Ming, Song, Yurong, Sun, Wenping et al. · 2012 · Cancer Research
  4. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
    Davide Angeli, Samanta Salvi, Gianluca Tedaldi · 2020 · International Journal of Molecular Sciences
  5. Functional Evaluation and Cancer Risk Assessment of BRCA2 Unclassified Variants
    Kangjian Wu, Shannon R. Hinson, Akihiro Ohashi, Daniel J. Farrugia, Patricia Wendt, Sean V. Tavtigian, Amie M. Deffenbaugh, David E. Goldgar, Fergus J. Couch · 2005 · Cancer Research
  6. Assessing Risk of Breast Cancer: A Review of Risk Prediction Models
    Geunwon Kim, Manisha Bahl · 2021 · Journal of Breast Imaging
  7. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits
    Sushmita Gordhandas, Barbara M. Norquist, Kathryn P. Pennington, Rachel Lynn Yung, Mary B. Laya, Elizabeth M. Swisher · 2019 · Gynecologic Oncology
  8. Optimal Selection of Individuals for BRCA Mutation Testing: A Comparison of Available Methods
    Paul Andrew James, Rebecca J Doherty, Marion Harris, Bickol Nanjan Mukesh, Alvin D. Milner, Mary‐Anne Young, Clare L. Scott · 2006 · Journal of Clinical Oncology
  9. Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics
    Martin Jakob Larsen, Mads Thomassen, Anne‐Marie Gerdes, Torben Arvid Kruse · 2014 · Breast Cancer Basic and Clinical Research
  10. Oncogenes induce the cancer-associated fibroblast phenotype: Metabolic symbiosis and “fibroblast addiction” are new therapeutic targets for drug discovery
    Michael P. Lisanti, Ubaldo Martinez‐Outschoorn, Federica Sotgia · 2013 · Cell Cycle
  11. Quality of life among patients after bilateral prophylactic mastectomy: a systematic review of patient-reported outcomes
    Shantanu N. Razdan, Vishal Patel, Sarah Jewell, Colleen M. McCarthy · 2015 · Quality of Life Research
  12. A novel germline PALB2 deletion in Polish breast and ovarian cancer patients
    Agnieszka Dansonka‐Mieszkowska, Anna Kluska, Joanna Moes-Sosnowska, Michalina Dąbrowska, Dorota Nowakowska, Anna Niwińska, Paweł Derlatka, Krzysztof Cendrowski, Jolanta Kupryjańczyk · 2010 · BMC Medical Genetics
  13. Risk‐reducing mastectomy and salpingo‐oophorectomy in unaffected BRCA mutation carriers: uptake and timing*
    Anne‐Bine Skytte, Anne‐Marie Gerdes, MK Andersen, Lone Sunde, K Brøndum‐Nielsen, Marianne Waldstrøm, Steen Kølvraa, D. G. Crüger · 2010 · Clinical Genetics
  14. Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer
    Jessica P. Gopie, Marc A.M. Mureau, Caroline Seynaeve, Moniek M. ter Kuile, Marian B. E. Menke‐Pluymers, Reinier Timman, Aad Tibben · 2012 · Familial Cancer
  15. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients
    Heidi S. Lumish, Hallie Steinfeld, Carrie Koval, Donna Russo, Elana Levinson, Julia Wynn, James K Duong, Wendy K. Chung · 2017 · Journal of Genetic Counseling
  16. Satisfaction with Prophylactic Mastectomy and Breast Reconstruction in Genetically Predisposed Women
    P.J.C. Bresser, Caroline Seynaeve, Arthur R. Van Gool, Cecile T.M. Brekelmans, Hanne E.J. Meijers-Heijboer, Albert N van Geel, Marian B. E. Menke‐Pluijmers, Hugo Joseph Duivenvoorden, Jan G.M. Klijn, Aad Tibben · 2006 · Plastic & Reconstructive Surgery
  17. Premature Menopause in Patients with BRCA1 Gene Mutation
    Izabella Rzepka-Górska, B Tarnowski, Anita Monika Chudecka-Glaz, Bohdan Górski, Dorota Zielińska, Aleksandra Tołoczko‐Grabarek · 2006 · Breast Cancer Research and Treatment
  18. A PALB2 mutation associated with high risk of breast cancer
    Melissa C. Southey, Zhi Ling Teo, James G. Dowty, Fabrice Odefrey, Daniel Jonathan Park, Marc D. Tischkowitz, Nelly Sabbaghian, Carmel Apicella, Graham B Byrnes, Ingrid Winship et al. · 2010 · Breast Cancer Research
  19. Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2
    Anna Marie Mulligan, Fergus J. Couch, Daniel Barrowdale, Susan M. Domchek, Diana Eccles, Heli A. Nevanlinna, Susan J. Ramus, Mark E. Robson, Mark E. Sherman, Amanda B. Spurdle et al. · 2011 · Breast Cancer Research
  20. Molecular Biological Aspects on Canine and Human Mammary Tumors
    Patricio Rivera, Henrik von Euler · 2010 · Veterinary Pathology
  21. Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis
    Xuan-Anh Phi, Sepideh Saadatmand, Geertruida H. de Bock, Ellen Warner, Francesco Sardanelli, Martin O. Leach, Christopher C. Riedl, Isabelle Trop, Maartje J. Hooning, Rodica Mandel et al. · 2016 · British Journal of Cancer
  22. Homologous Recombination Deficiencies and Hereditary Tumors
    Hideki Yamamoto, Akira Hirasawa · 2021 · International Journal of Molecular Sciences
  23. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation
    Thomas G. P. Grünewald, Ulrike Kämmerer, C Winkler, Detlev Schindler, Albert Sickmann, Arnd Hönig, Elke Butt · 2007 · British Journal of Cancer
  24. Modifiers of risk of hereditary breast cancer
    Steven Alexander Narod · 2006 · Oncogene
  25. The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations
    Michael Fatouros, Georgios Baltoyiannis, Dimitrios H Roukos · 2007 · Annals of Surgical Oncology
  26. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals
    Terri Febbraro, Katina M. Robison, Jennifer Scalia Wilbur, Jessica Kent Laprise, Amy J. Bregar, Vrishali Lopes, Robert Duffy Legare, Ashley R. Stuckey · 2015 · Gynecologic Oncology
  27. Mammographic Density and Breast Cancer Risk: Evaluation of a Novel Method of Measuring Breast Tissue Volumes
    Norman F. Boyd, Lisa J Martin, Anoma Gunasekara, Olga Melnichouk, Gord Maudsley, Chris Peressotti, Martin J. Yaffe, Salomon Minkin · 2009 · Cancer Epidemiology Biomarkers & Prevention
  28. BRCA1 Mutation and Young Age Predict Fast Breast Cancer Growth in the Dutch, United Kingdom, and Canadian Magnetic Resonance Imaging Screening Trials
    Madeleine M. A. Tilanus‐Linthorst, Inge-Marie Obdeijn, Wim C.J. Hop, Petrina A. Causer, Martin O. Leach, Ellen Warner, Linda J. Pointon, Kimberley A. Hill, Jan G.M. Klijn, Ruth M. L. Warren et al. · 2007 · Clinical Cancer Research
  29. Hereditary ovarian cancer
    Antonio Dello Russo, Valentina Calò, Loredana Bruno, Sérgio Rizzo, Viviana Bazan, Gaetana Di Fede · 2008 · Critical Reviews in Oncology/Hematology
  30. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort
    Kari Lassen Ring, Amanda S. Bruegl, Brian A Allen, Eric P. Elkin, Nanda Singh, Anne‐Renee Hartman, Molly S. Daniels, Russell R. Broaddus · 2016 · Modern Pathology
  31. Triple‑negative breast cancer: A run‑through of features, classification and current therapies (Review)
    Meghana Manjunath, Bibha Choudhary · 2021 · Oncology Letters
  32. Breast cancer genome-wide association studies: there is strength in numbers
    Daniele Fanale, Valeria Amodeo, Lidia Rita Corsini, Stefania Rizzo, Viviana Bazan, Antonio Dello Russo · 2011 · Oncogene
  33. Translational advances regarding hereditary breast cancer syndromes
    Michele Maiko Gage, Daniel J Wattendorf, Leonard R. Henry · 2012 · Journal of Surgical Oncology
  34. Genetic architecture of cancer and other complex diseases: lessons learned and future directions
    Lucia A. Hindorff, Elizabeth M. Gillanders, Teri A. Manolio · 2011 · Carcinogenesis
  35. Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
    Antonis C. Antoniou, Olga M. Sinilnikova, Lesley McGuffog, Sue C. Healey, Heli A. Nevanlinna, Tuomas Heikkinen, Jacques Simard, Amanda B. Spurdle, Jonathan Beesley, Xiaoqing Chen et al. · 2009 · Human Molecular Genetics
  36. The biological effects and clinical implications of BRCA mutations: where do we go from here?
    Dominique Stoppa‐Lyonnet · 2016 · European Journal of Human Genetics
  37. An update on PARP inhibitors for the treatment of cancer
    Marcia Hall, Sarah Benafif · 2015 · OncoTargets and Therapy
  38. Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling
    S. Richter, Iman Haroun, Tracy Graham, Andrea F. Eisen, Alex Kiss, Ellen Warner · 2013 · Annals of Oncology
  39. Support of the ‘fallopian tube hypothesis’ in a prospective series of risk-reducing salpingo-oophorectomy specimens
    Welmoed Reitsma, Geertruida H. de Bock, Jan C. Oosterwijk, Joost Bart, Harry Hollema, Marian J.E. Mourits · 2012 · European Journal of Cancer
  40. Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In Situ
    Elizabeth B. Claus · 2005 · JAMA
  41. Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations
    Kelly A. Metcalfe, Jan Lubiński, Henry T. Lynch, Parviz Ghadirian, William David Foulkes, Charmaine Kim‐Sing, Susan L. Neuhausen, Nadine Tung, Barry P. Rosen, Jacek Gronwald et al. · 2010 · JNCI Journal of the National Cancer Institute
  42. Current approach to fertility preservation by embryo cryopreservation
    Giuliano Bedoschi, Kutluk Oktay · 2013 · Fertility and Sterility
  43. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population
    Cecelia A. Bellcross, Amy A. Lemke, Laura S. Pape, Angela Tess, Lorraine T. Meisner · 2009 · Genetics in Medicine
  44. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2
    Lindsey E. Minion, Jill S. Dolinsky, Dana M. Chase, Charles L.M. Dunlop, Elizabeth Chao, Bradley J. Monk · 2015 · Gynecologic Oncology
  45. Ovarian Aging in Women With BRCA Germline Mutations
    Wayne T. Lin, Shiny Titus, FRED H. MOY, Elizabeth Sarah Ginsburg, Kutluk Oktay · 2017 · The Journal of Clinical Endocrinology & Metabolism
  46. Targeting tumor suppressor genes for cancer therapy
    Yunhua Liu, Xiaoxiao Hu, Cecil Han, Liana Wang, Xinna Zhang, Xiaoming He, Xiongbin Lu · 2015 · BioEssays
  47. Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries
    Ava Kwong, Vivian Yvonne Shin, John Chi Wang Ho, Eunyoung Kang, Seigo Nakamura, Soo‐Hwang Teo, Ann S. G. Lee, Jen-Hwei Sng, Ophira Ginsburg, Allison W. Kurian et al. · 2015 · Journal of Medical Genetics
  48. Chemopreventive properties of 3,3′-diindolylmethane in breast cancer: evidence from experimental and human studies
    Cynthia A. Thomson, Emily Ho, Meghan B. Strom · 2016 · Nutrition Reviews
  49. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers
    Haitham Tuffaha, Andrew Mitchell, Robyn Lynne Ward, Luke B. Connelly, James R.G. Butler, Sarah Norris, Paul Scuffham · 2018 · Genetics in Medicine
  50. Electronic health records and polygenic risk scores for predicting disease risk
    Ruowang Li, Yong Chen, Marylyn DeRiggi Ritchie, Jason H. Moore · 2020 · Nature Reviews Genetics
  51. Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell viability
    Bingyun Li, Luo, Bingbing Jiang, Li, Jiang, Yi Chen · 2012 · International Journal of Nanomedicine
  52. Hereditary Breast Cancer and the BRCA1-Associated FANCJ/BACH1/BRIP1
    Cantor, Sharon B, Guillemette, Shawna · 2011 · Future Oncology
  53. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study
    Marline G. Harmsen, Marieke Arts-de Jong, Nicoline Hoogerbrugge, Angela H.E.M. Maas, Judith B. Prins, Johan Bulten, Steven Teerenstra, Eddy Adang, Jurgen M.J. Piek, Helena C. van Doorn et al. · 2015 · BMC Cancer
  54. Discovering moderate-risk breast cancer susceptibility genes
    Antoinette Hollestelle, Marijke Wasielewski, John W.M. Martens, Mieke E. M. Schutte · 2010 · Current Opinion in Genetics & Development
  55. Patterns and mechanisms of structural variations in human cancer
    Kijong Yi, Young Seok Ju · 2018 · Experimental & Molecular Medicine
  56. Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy
    Jonathan S. Berek, Eva Chalas, Mitchell I. Edelson, David H. Moore, William M. Burke, William A. Cliby, Andrew Berchuck · 2010 · Obstetrics and Gynecology
  57. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia
    Diana Torres, Muhammad Usman Rashid, Fabián Gil, Ángela Umaña, Giancarlo Ramelli, José Fernando Robledo, Mauricio Tawil, Lilián Torregrosa, Ignacio Briceño, Ute Hamann · 2006 · Breast Cancer Research and Treatment
  58. Multi-disciplinary summit on genetics services for women with gynecologic cancers: A Society of Gynecologic Oncology White Paper
    Leslie M. Randall, Bhavana Pothuri, Elizabeth M. Swisher, John Paul Diaz, Adam H. Buchanan, Catherine Witkop, C. Bethan Powell, Ellen Blair Smith, Mark E. Robson, Jeff A. Boyd et al. · 2017 · Gynecologic Oncology
  59. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark
    Marie Søgaard, Susanne K. Kjær, Mark J. Cox, Eva L. Woźniak, Estrid Vilma Solyom Høgdall, Claus Kim Høgdall, Jan Blaakær, Ian J. Jacobs, Simon A. Gayther, Susan J. Ramus · 2008 · Clinical Cancer Research
  60. BRCA Mutations and Breast Cancer Prevention
    Joanne Kotsopoulos · 2018 · Cancers
  61. The Relative Contribution of Point Mutations and Genomic Rearrangements in BRCA1 and BRCA2 in High-Risk Breast Cancer Families
    Maurizia Dalla Palma, Susan M. Domchek, Jill E. Stopfer, Julie Erlichman, Jill D. Siegfried, Jessica Tigges-Cardwell, Bernard A. Mason, Timothy Richard Rebbeck, Katherine L. Nathanson · 2008 · Cancer Research
  62. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome
    Dimitrios H Roukos, Evangelos C. Briasoulis · 2007 · Nature Clinical Practice Oncology
  63. Genetic susceptibility to breast cancer
    Angela R. Bradbury, Olufunmilayo Ibironke Olopade · 2007 · Reviews in Endocrine and Metabolic Disorders
  64. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations
    Murray Joseph Casey, Carrie Synder, Chhanda Bewtra, Steven Alexander Narod, Patrice A. Watson, Henry T. Lynch · 2005 · Gynecologic Oncology
  65. Contribution of germline BRCA1 and BRCA2sequence alterations to breast cancer in Northern India
    Sunita Saxena, Anurupa Chakraborty, Mishi Kaushal, S.A. Kotwal, Dinesh Bhatanager, R. S. Mohil, Chintamani Chintamani, Anil K Aggarwal, Veena K Sharma, Prakash Chand Sharma et al. · 2006 · BMC Medical Genetics
  66. Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer
    Deborah L. Cragun, Devon E. Bonner, J. Kim, Mohammad Reza Akbari, Steven Alexander Narod, A. Gomez-Fuego, Jennifer García, Susan Thomas Vadaparampil, Tuya Pal · 2015 · Breast Cancer Research and Treatment
  67. Penetrance Analysis of the PALB2 c.1592delT Founder Mutation
    Hannele Erkko, James G. Dowty, Jenni Nikkilä, Kirsi Syrjäkoski, Arto Mannermaa, Katri Pylkäs, Melissa C. Southey, Kaija Holli, Anne H. Kallioniemi, Arja Jukkola‐Vuorinen et al. · 2008 · Clinical Cancer Research
  68. The Tumor Suppressor PALB2: Inside Out
    Mandy Ducy, Laura Sesma-Sanz, Laure Guitton-Sert, Anahita Lashgari, Yuandi Gao, Nadine Brahiti, Amélie Rodrigue, Guillaume Margaillan, Marie‐Christine Caron, Jacques Côté et al. · 2019 · Trends in Biochemical Sciences
  69. Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case–control study
    Joanne Kotsopoulos, Clifford Lawrence Librach, Jan Lubiński, Jacek Gronwald, Charmaine Kim‐Sing, Parviz Ghadirian, Henry T. Lynch, Pål Møller, William David Foulkes, Susan Randall et al. · 2008 · Cancer Causes & Control
  70. A literature review of the psychological impact of genetic testing on breast cancer patients
    Kathryn J. Schlich‐Bakker, Herman F. J. ten Kroode, Margreet G.E.M. Ausems · 2005 · Patient Education and Counseling
  71. Cell and tissue interactions in carcinogenesis and metastasis and their clinical significance
    David Tarin · 2010 · Seminars in Cancer Biology
  72. Inherited Genetic Susceptibility to Breast Cancer
    Maya Ghoussaini, Paul D.P. Pharoah, Douglas F. Easton · 2013 · American Journal Of Pathology
  73. Population-based estimates of breast cancer risks associated withATMgene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry
    Jonine L. Bernstein, Sharon N. Teraoka, Melissa C. Southey, Mark A. Jenkins, Irene Louise Andrulis, Julia A. Knight, Esther M. John, Robert H. Lapinski, Abigail L. Wolitzer, Alice S. Whittemore et al. · 2006 · Human Mutation
  74. The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment
    Clémence Basse, Michel Arock · 2014 · International Journal of Cancer
  75. New perspectives on targeted therapy in ovarian cancer
    Jermaine Ian George Coward, Kathryn Middleton, Felicity Murphy · 2015 · International Journal of Women s Health
  76. Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy
    Lokesh Agrawal, Kelly Bonner Engel, Sarah R. Greytak, Helen M. Moore · 2017 · Seminars in Cancer Biology
  77. The role of BRCA mutation testing in determining breast cancer therapy
    Alison H. Trainer, Craig R. Lewis, Kathy Tucker, Bettina Meiser, Michael Leonard Friedlander, Robyn Lynne Ward · 2010 · Nature Reviews Clinical Oncology
  78. Pancreatic Cancer Genetics
    Laufey Thora Amundadottir · 2016 · International Journal of Biological Sciences
  79. Multistep Level Sections to Detect Occult Fallopian Tube Carcinoma in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations
    Joseph T. Rabban, Ellen Krasik, Lee-may Chen, C. Bethan Powell, Beth Crawford, Charles J. Zaloudek · 2009 · The American Journal of Surgical Pathology
  80. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland
    Jacek Gronwald, Tomasz Byrski, Tomasz Huzarski, Cezary Cybulski, Ping Sun, Anna Tulman, Steven Alexander Narod, Jan Lubiński · 2005 · Breast Cancer Research and Treatment
  81. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
    Zsofia Kinga Stadler, Erin E. Salo‐Mullen, Sujata M. Patil, Maria Catherine Pietanza, Joseph Vijai, Emmanouil S. Saloustros, Nichole A. L. Hansen, Noah D. Kauff, Robert C. Kurtz, David Paul Kelsen et al. · 2011 · Cancer
  82. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations
    Jaya Singh, Nishita Thota, Suhasini Singh, Shila Padhi, Puja Mohan, Shivani Deshwal, Soumit Sur, Mithua Ghosh, Amit Agarwal, Ramesh Sarin et al. · 2018 · Breast Cancer Research and Treatment
  83. Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21
    Ali Hussain, Véronique Voisin, Stephanie Poon, Christina Karamboulas, Ngoc H.B. Bui, Jalna Meens, Julia Dmytryshyn, Victor W. Ho, Kwan Ho Tang, Joshua Paterson et al. · 2020 · The Journal of Experimental Medicine
  84. Early Detection Biomarkers for Ovarian Cancer
    Sreeja Sarojini, Ayala Tamir, Heejin Lim, Shihong Li, Shifang Zhang, Andre Henri Goy, Andrew L. Pecora, K. Stephen Suh · 2012 · Journal of Oncology
  85. The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain
    Roger Laughlin Milne, Ana Osório, Teresa Ramón y Cajal, Ana Isabel Vega, Gemma Llort, Miguel de la Hoya, Orland Dı́ez, M. Carmen Alonso, Conxi Lázaro, Ignacio Blanco et al. · 2008 · Clinical Cancer Research
  86. Breast Cancer in Young Women
    Deborah Axelrod, Julia Anne Smith, Davida Kornreich, Eve Grinstead, Baljit Singh, Joan F Cangiarella, Amber Azniv Guth · 2008 · Journal of the American College of Surgeons
  87. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
    TNT Trial TMG, BCSC (UK), Lindsay B. Robertson, Helen Hanson, S. Seal, Margaret Warren-Perry, Deborah Hughes, Imran Howell, Clare Turnbull, Richard S. Houlston, Susan Shanley et al. · 2012 · British Journal of Cancer
  88. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers
    Joanne Kotsopoulos, Jan Lubiński, Pål Møller, Henry T. Lynch, Christian Fridolin Singer, Charis Eng, Susan L. Neuhausen, Beth Y. Karlan, Charmaine Kim‐Sing, Tomasz Huzarski et al. · 2014 · Breast Cancer Research and Treatment
  89. Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers
    Mary Stanley Beattie, Beth Crawford, Feng Lin, Eric Vittinghoff, John L. Ziegler · 2009 · Genetic Testing and Molecular Biomarkers
  90. X Inactive–Specific Transcript RNA Coating and Genetic Instability of the X Chromosome in BRCA1 Breast Tumors
    Anne Vincent‐Salomon, Carine Ganem‐Elbaz, Élodie Manié, Virginie Raynal, Xavier Sastre‐Garau, Dominique Stoppa‐Lyonnet, Marc‐Henri Stern, Édith Heard · 2007 · Cancer Research
  91. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers
    Roger Laughlin Milne, Antonis C. Antoniou · 2011 · Annals of Oncology
  92. At the Crossroads Between Neurodegeneration and Cancer: A Review of Overlapping Biology and Its Implications
    Alexander Lee Houck, Sahba Seddighi, Jane Ann Driver · 2018 · Current Aging Science
  93. BRCA1 and BRCA2 mutations and the risk for colorectal cancer
    Victoria Sopik, Catherine Phelan, Cezary Cybulski, Steven Alexander Narod · 2014 · Clinical Genetics
  94. Parity and breast cancer risk among BRCA1 and BRCA2mutation carriers
    Antonis C. Antoniou, Andrew Shenton, Eamonn Richard Maher, Emma Watson, Emma Roisin Woodward, Fiona I. Lalloo, Douglas F. Easton, D. Gareth Evans · 2006 · Breast Cancer Research
  95. Surveillance of women at high risk for hereditary ovarian cancer is inefficient
    Angèle L.M. Oei, Leon F.A.G. Massuger, Johan Bulten, M J Ligtenberg, Nicoline Hoogerbrugge, Joanne A. de Hullu · 2006 · British Journal of Cancer
  96. The Use of Breast Imaging to Screen Women at High Risk for Cancer
    Edward A. Sickles · 2010 · Radiologic Clinics of North America
  97. Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125
    Chirag Shah, Kimberly Anne Lowe, Pamela J. Paley, Erin R. Wallace, Garnet L. Anderson, Martin W. McIntosh, M. Robyn Andersen, Nathalie Scholler, Lindsay A. Bergan, Jason D. Thorpe et al. · 2009 · Cancer Epidemiology Biomarkers & Prevention
  98. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers
    Eli Marie Grindedal, Cecilie Heramb, Inga Karsrud, Sarah Louise Ariansen, Lovise Mæhle, Dag Erik Undlien, Jan Norum, Ellen Schlichting · 2017 · BMC Cancer
  99. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction
    Michelle R. Jones, Daniella Kamara, Beth Y. Karlan, Paul D.P. Pharoah, Simon A. Gayther · 2017 · Gynecologic Oncology
  100. BRCA Patients and Clinical Collectives
    Pascale Bourret · 2005 · Social Studies of Science